Safety and efficacy of nivolumab as a second line therapy in metastatic renal cell carcinoma: a retrospective chart review

Znanstveni rad - Izvorni znanstveni rad

• Autor: Marija Gamulin
• Autor: Eric Nham
• Autor: Deni Rkman
• Autor: Zrna Antunac
• Autor: Zrna Golubić
• Autor: Robert Likić
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet; (KATEDRA ZA INTERNU MEDICINU)
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti; Interna medicina

Sažetak (engleski)

Aim To assess diseases outcomes and tolerability of real-life second-line nivolumab in a series of metastatic renal cell carcinoma (mRCC) patients. ----- Methods This retrospective chart review involved prospectively monitored patients (named patient program) treated with second-line nivolumab for mRCC at the University Hospital Centre Zagreb from February 2016 to March 2018. ----- Results The study enrolled 30 patients, 5 of whom (16.7%) had a complete response. The mean ± standard deviation therapeutic response time to nivolumab treatment was 14.07 ± 8.92 months, with a minimum treatment duration of 2 months and a maximum of 24 months. The median duration of therapy was 17 months (mean: 15.8 months; range: 3-24 months), and 50% (n = 15/30) of patients remained alive at the end of follow up. The most common adverse events associated with nivolumab were fatigue (26.67%; n = 8/30), anemia (10.0%; n = 3/30), adrenal insufficiency (6.67%; n = 2/30: G1 = 1, G2 = 1), grade 2 pneumonitis (6.67%; n = 2/30), grade 2 neuropathy (6.67%; n = 2/30), rash (6.67%; n = 2/30: G1 = 1, G2 = 1), and hepatitis (3.33%; n = 1/30). ----- Conclusion The present study indicates acceptable patient responses and tolerability of nivolumab in mRCC.

• Ključne riječi (engleski): Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Immunological / adverse effects; Antineoplastic Agents, Immunological / therapeutic use; Carcinoma, Renal Cell / drug therapy; Carcinoma, Renal Cell / pathology; Female; Humans; Kidney Neoplasms / drug therapy; Kidney Neoplasms / pathology; Male; Middle Aged; Nivolumab / adverse effects; Nivolumab / therapeutic use; Retrospective Studies; Treatment Outcome
• Jezik: engleski
• Vrsta publikacije: Znanstveni rad - Izvorni znanstveni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: Croatian Medical Journal
• Brojčani podaci: vol. 61, br. 4, str. 326-332
• p-ISSN: 0353-9504
• e-ISSN: 1332-8166
• DOI: https://doi.org/10.3325/cmj.2020.61.326
• URN:NBN: urn:nbn:hr:105:651557
• Datum objave publikacije: 2020-08-01
• URL dokumenta: http://www.cmj.hr/2020/61/4/32881430.htm
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2020-10-28 07:59:40